semaglutide news today FDA warns Novo Nordisk of unreported GLP-1 side effects The FDA announced plans to

This makes it a more credible option for people whose blood work or clinical picture suggests a genuine need those with high toxic load, recovering from illness, or managing chronic inflammation

You will likely lose some weight on the scale

Thyroid disorders and obesity often occur together, affecting roughly 20% of adults with hypothyroidism who also struggle with weight gain

For some individuals, diet and exercise alone may not lead to sustainable results due to hormonal signaling that affects hunger and fullness

That regulatory status is important for patients to understand, but it should be separated from the biological research

The oral segment is projected to witness the fastest CAGR from 2025 to 2032, driven by the growing demand for needle-free alternatives and the launch of oral GLP-1 receptor agonists such as Rybelsus (oral semaglutide) and future pipeline products such as orforglipron